Abcam, ab180675, Anti-RIG-I/DDX58 antibody [EPR18629]

Size: 100µL / 1mL
Anti-RIG-I/DDX58 antibody [EPR18629] (ab180675) is a rabbit monoclonal antibody detecting RIG-I/DDX58 in Western Blot, IP . Suitable for Human . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency - Over 10 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18629,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-RIG-I/DDX58 antibody [EPR18629] (ab180675) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP) in Human samples.
What is the molecular weight of RIG-I/DDX58?
Anti-RIG-I/DDX58 [EPR18629] (ab180675) specifically detects a band for RIG-I/DDX58 (UniProt: O95786) at a molecular weight of 107kDa.
Trusted by the scientific community
Anti-RIG-I/DDX58 [EPR18629] (ab180675) was first used in a scientific publication in 2015 and has been cited over 10 times in peer-reviewed journals.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Specificity confirmed
The specificity of Anti-RIG-I/DDX58 antibody [EPR18629] (ab180675) has been confirmed by Western blot testing in RIGI Knockout HAP1 cell line,
ab267117
Other related products
We have a range of other formats of antibody clone [EPR18629] also available for your convenience: ab180675, Carrier free -
ab240230
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RIG-I also known as DDX58 is an important protein with mass of approximately 102 kDa. This protein acts as a cytosolic sensor for viral double-stranded RNA playing an essential role in the detection of viral infections. It is expressed in many cell types including immune and epithelial cells. RIG-I consists of two N-terminal caspase activation and recruitment domains (CARDs) a DExD/H box helicase domain and a C-terminal regulatory domain. These domains enable RIG-I to recognize and bind viral RNA initiating downstream signaling for immune responses.
Biological function summary
RIG-I contributes significantly to the innate immune response. It acts to sense viral RNA and triggers the production of type I interferons and other pro-inflammatory cytokines. This protein functions as part of a complex that includes MAVS (mitochondrial antiviral signaling protein) and other signaling adapters. Upon activation RIG-I undergoes a conformational change leading to the exposure of its CARDs which interact with CARDs of MAVS facilitating downstream signaling to induce an antiviral state in host cells.
Pathways
RIG-I plays a central role in the RNA sensing pathway critical for antiviral immunity. This pathway involves several steps beginning with the recognition of viral RNA leading to the activation of interferon regulatory factors like IRF3 and IRF7 as well as nuclear factor kappa B (NF-κB). These factors then promote the expression of interferon-stimulated genes (ISGs). RIG-I also relates closely to the Jak-STAT signaling pathway which is activated by interferons and enhances the transcription of ISGs further amplifying the antiviral response.
RIG-I is often associated with viral infections such as hepatitis C and influenza. By detecting viral RNA RIG-I activates immune responses that help to control these infections. However dysfunction or aberrations in RIG-I signaling can lead to autoimmune disorders such as Aicardi-Goutières syndrome where there is an inappropriate response to self nucleic acids. In these disease contexts RIG-I interacts with MAVS and indirectly with proteins involved in regulating immune responses such as STING which plays a role in the innate immune response against DNA viruses.